Gyre Therapeutics (NASDAQ:GYRE) Releases Earnings Results, Misses Expectations By $0.06 EPS

Gyre Therapeutics (NASDAQ:GYRE) announced its quarterly earnings data on Friday, August 7th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06), FiscalAI reports. The company had revenue of $29.11 million during the quarter, compared to analyst estimates of $26.49 million. Gyre Therapeutics had a negative net margin of 15.47% and a negative return on equity of 6.57%.

Gyre Therapeutics Stock Down 1.9%

GYRE traded down $0.13 during trading on Friday, hitting $6.55. 7,814 shares of the stock were exchanged, compared to its average volume of 86,938. The firm has a market capitalization of $730.39 million, a P/E ratio of -31.19 and a beta of 1.92. Gyre Therapeutics has a 1-year low of $5.44 and a 1-year high of $9.42. The stock has a fifty day moving average price of $6.47 and a two-hundred day moving average price of $6.95.

Hedge Funds Weigh In On Gyre Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC lifted its stake in shares of Gyre Therapeutics by 38.3% in the 4th quarter. Barclays PLC now owns 18,531 shares of the company’s stock worth $131,000 after acquiring an additional 5,135 shares during the period. Geode Capital Management LLC increased its stake in shares of Gyre Therapeutics by 13.0% during the fourth quarter. Geode Capital Management LLC now owns 423,222 shares of the company’s stock worth $2,989,000 after acquiring an additional 48,602 shares during the period. State Street Corp increased its stake in shares of Gyre Therapeutics by 10.7% during the fourth quarter. State Street Corp now owns 202,225 shares of the company’s stock worth $1,428,000 after acquiring an additional 19,472 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Gyre Therapeutics by 37.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock worth $1,194,000 after purchasing an additional 45,772 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in Gyre Therapeutics during the third quarter worth about $267,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on GYRE shares. Zacks Research downgraded Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 18th. Wall Street Zen cut Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Gyre Therapeutics in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average target price of $16.00.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.